CL2021000046A1 - Degradadores selectivos del receptor de estrógeno - Google Patents
Degradadores selectivos del receptor de estrógenoInfo
- Publication number
- CL2021000046A1 CL2021000046A1 CL2021000046A CL2021000046A CL2021000046A1 CL 2021000046 A1 CL2021000046 A1 CL 2021000046A1 CL 2021000046 A CL2021000046 A CL 2021000046A CL 2021000046 A CL2021000046 A CL 2021000046A CL 2021000046 A1 CL2021000046 A1 CL 2021000046A1
- Authority
- CL
- Chile
- Prior art keywords
- estrogen receptor
- selective estrogen
- breakers
- degradators
- serds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Professional, Industrial, Or Sporting Protective Garments (AREA)
- Finger-Pressure Massage (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se proporcionan novedosos degradadores selectivos del receptor de estrógeno (SERD) de acuerdo con la fórmula; sales farmacéuticamente aceptables, composiciones farmacéuticas, usos y métodos de uso de estos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862697100P | 2018-07-12 | 2018-07-12 | |
US201962825172P | 2019-03-28 | 2019-03-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021000046A1 true CL2021000046A1 (es) | 2021-06-25 |
Family
ID=67480324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021000046A CL2021000046A1 (es) | 2018-07-12 | 2021-01-07 | Degradadores selectivos del receptor de estrógeno |
Country Status (33)
Country | Link |
---|---|
US (1) | US20210260052A1 (es) |
EP (1) | EP3820874B1 (es) |
JP (1) | JP7085056B2 (es) |
KR (1) | KR102577142B1 (es) |
CN (1) | CN112424205B (es) |
AU (1) | AU2019299952B2 (es) |
BR (1) | BR112020025381A2 (es) |
CA (1) | CA3105491C (es) |
CL (1) | CL2021000046A1 (es) |
CO (1) | CO2021000041A2 (es) |
CR (1) | CR20210006A (es) |
DK (1) | DK3820874T3 (es) |
EC (1) | ECSP21001786A (es) |
ES (1) | ES2932867T3 (es) |
FI (1) | FI3820874T3 (es) |
HR (1) | HRP20230080T1 (es) |
HU (1) | HUE061032T2 (es) |
IL (1) | IL279990B2 (es) |
JO (1) | JOP20210004A1 (es) |
LT (1) | LT3820874T (es) |
MD (1) | MD3820874T2 (es) |
MX (1) | MX2021000377A (es) |
NZ (1) | NZ771719A (es) |
PE (1) | PE20211245A1 (es) |
PH (1) | PH12021550048A1 (es) |
PL (1) | PL3820874T3 (es) |
PT (1) | PT3820874T (es) |
RS (1) | RS63876B1 (es) |
SA (1) | SA521421006B1 (es) |
SG (1) | SG11202100145YA (es) |
SI (1) | SI3820874T1 (es) |
UA (1) | UA125890C2 (es) |
WO (1) | WO2020014440A1 (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11730726B2 (en) | 2018-07-11 | 2023-08-22 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Dimeric immuno-modulatory compounds against cereblon-based mechanisms |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108366996B (zh) | 2015-10-01 | 2021-04-09 | 奥列马制药公司 | 四氢-1H-吡啶[3,4-b]吲哚类抗雌激素药物 |
TWI702219B (zh) * | 2018-07-12 | 2020-08-21 | 美商美國禮來大藥廠 | 選擇性雌激素受體降解劑 |
CN117715902A (zh) * | 2021-08-31 | 2024-03-15 | 卫材R&D管理有限公司 | 单环吡啶衍生物的制造方法 |
US11926634B2 (en) | 2022-02-01 | 2024-03-12 | Eli Lilly And Company | Processes for the preparation of selective estrogen receptor degraders |
WO2024042157A1 (en) | 2022-08-25 | 2024-02-29 | Sanofi | Novel substituted quinoline and tetrahydronaphthalene carboxylic acid derivatives and therapeutic uses thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6756388B1 (en) * | 1993-10-12 | 2004-06-29 | Pfizer Inc. | Benzothiophenes and related compounds as estrogen agonists |
US5521214A (en) * | 1995-01-25 | 1996-05-28 | Eli Lilly And Company | Methods of inhibiting environmental estrogens |
JPH10204082A (ja) * | 1996-10-25 | 1998-08-04 | Eli Lilly & Co | 選択的エストロゲンレセプターモジュレーターとしての活性を有する置換されたベンゾ[b]チオフェン化合物 |
DE60210283T2 (de) | 2001-05-22 | 2006-11-09 | Eli Lilly And Co., Indianapolis | 2-substituierte 1,2,3,4-tetrahydrochinoline und derivate davon, zusammensetzungen und verfahren |
US7329654B2 (en) | 2001-12-19 | 2008-02-12 | Janssen Pharmaceutica N.V. | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators |
NZ536291A (en) * | 2002-04-19 | 2006-09-29 | Signal Pharm Inc | Benzopyranone compounds, compositions thereof, and methods of treatment therewith |
DE20301728U1 (de) * | 2002-10-11 | 2004-03-11 | Ligand Pharmaceuticals, Inc., San Diego | 5-substituierte 7,9-Difluor-5H-Chromeno(3,4-f) -Chinolin-Verbindungen als selektive Progesteronrezeptormodulator-Verbindungen |
CL2004000985A1 (es) * | 2003-05-16 | 2005-01-14 | Wyeth Corp | Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc |
EP1709021B1 (en) * | 2004-01-22 | 2010-08-04 | Eli Lilly And Company | Selective estrogen receptor modulators for the treatment of vasomotor symptoms |
EP1789420A2 (en) * | 2004-09-07 | 2007-05-30 | Wyeth, A Corporation of the State of Delaware | 6H-[1]BENZOPYRANO[4,3-b]QUINOLINES AND THEIR USE AS ESTROGENIC AGENTS |
US20080221163A1 (en) | 2005-01-18 | 2008-09-11 | Jeffrey Alan Dodge | Selective Estrogen Receptor Modulators |
MX2015016171A (es) | 2013-06-19 | 2016-08-08 | Seragon Pharmaceuticals Inc | Moduladores del receptor de estrogeno de azetidina y usos de los mismos. |
EP3233828B1 (en) * | 2014-12-18 | 2020-03-04 | F. Hoffmann-La Roche AG | Estrogen receptor modulators and uses thereof |
JP6768711B2 (ja) * | 2015-05-26 | 2020-10-14 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 複素環式エストロゲン受容体モジュレーター及びその使用 |
JP7241542B2 (ja) * | 2016-04-08 | 2023-03-17 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | テトラヒドロイソキノリン エストロゲン受容体モジュレーター及びその使用 |
JP7229162B2 (ja) * | 2017-01-06 | 2023-02-27 | ジー1 セラピューティクス, インコーポレイテッド | 癌の治療に対する併用療法 |
TWI702219B (zh) * | 2018-07-12 | 2020-08-21 | 美商美國禮來大藥廠 | 選擇性雌激素受體降解劑 |
-
2019
- 2019-07-11 AU AU2019299952A patent/AU2019299952B2/en active Active
- 2019-07-11 PE PE2021000017A patent/PE20211245A1/es unknown
- 2019-07-11 CN CN201980046170.4A patent/CN112424205B/zh active Active
- 2019-07-11 LT LTEPPCT/US2019/041342T patent/LT3820874T/lt unknown
- 2019-07-11 CR CR20210006A patent/CR20210006A/es unknown
- 2019-07-11 NZ NZ771719A patent/NZ771719A/en unknown
- 2019-07-11 JO JOP/2021/0004A patent/JOP20210004A1/ar unknown
- 2019-07-11 FI FIEP19746252.6T patent/FI3820874T3/fi active
- 2019-07-11 WO PCT/US2019/041342 patent/WO2020014440A1/en unknown
- 2019-07-11 PT PT197462526T patent/PT3820874T/pt unknown
- 2019-07-11 JP JP2021500586A patent/JP7085056B2/ja active Active
- 2019-07-11 DK DK19746252.6T patent/DK3820874T3/da active
- 2019-07-11 KR KR1020217000473A patent/KR102577142B1/ko active IP Right Grant
- 2019-07-11 MX MX2021000377A patent/MX2021000377A/es unknown
- 2019-07-11 BR BR112020025381-2A patent/BR112020025381A2/pt unknown
- 2019-07-11 UA UAA202100103A patent/UA125890C2/uk unknown
- 2019-07-11 SI SI201930407T patent/SI3820874T1/sl unknown
- 2019-07-11 HU HUE19746252A patent/HUE061032T2/hu unknown
- 2019-07-11 HR HRP20230080TT patent/HRP20230080T1/hr unknown
- 2019-07-11 RS RS20230014A patent/RS63876B1/sr unknown
- 2019-07-11 SG SG11202100145YA patent/SG11202100145YA/en unknown
- 2019-07-11 CA CA3105491A patent/CA3105491C/en active Active
- 2019-07-11 EP EP19746252.6A patent/EP3820874B1/en active Active
- 2019-07-11 ES ES19746252T patent/ES2932867T3/es active Active
- 2019-07-11 PL PL19746252.6T patent/PL3820874T3/pl unknown
- 2019-07-11 US US17/254,991 patent/US20210260052A1/en active Pending
- 2019-07-11 MD MDE20210464T patent/MD3820874T2/ro unknown
-
2021
- 2021-01-06 CO CONC2021/0000041A patent/CO2021000041A2/es unknown
- 2021-01-06 IL IL279990A patent/IL279990B2/en unknown
- 2021-01-07 CL CL2021000046A patent/CL2021000046A1/es unknown
- 2021-01-08 PH PH12021550048A patent/PH12021550048A1/en unknown
- 2021-01-11 EC ECSENADI20211786A patent/ECSP21001786A/es unknown
- 2021-01-12 SA SA521421006A patent/SA521421006B1/ar unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11730726B2 (en) | 2018-07-11 | 2023-08-22 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Dimeric immuno-modulatory compounds against cereblon-based mechanisms |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2021000043A2 (es) | Degradadores selectivos del receptor de estrógeno | |
CL2021000046A1 (es) | Degradadores selectivos del receptor de estrógeno | |
EA201990565A1 (ru) | Кристаллический 19-нор c3,3-дизамещенный c21-n-пиразолил стероид | |
NI202000078A (es) | Compuestos heteroaril tetracíclicos | |
CL2018000730A1 (es) | Compuestos heterocíclicos y usos de los mismos | |
CL2017003258A1 (es) | Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
CL2016002148A1 (es) | Derivados de fenilen-1,5-diamina 2,4-disustituidos y aplicaciones de los mismos, y composiciones farmacéuticas y composiciones farmacéuticamente aceptables preparadas a partir de los mismos. | |
CU24487B1 (es) | Compuestos de tetrahidroquinolinona sustituidos como moduladores de gamma ror | |
CR8847A (es) | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y usos de los mismos | |
CR20160291A (es) | Análogos de cortistatina y síntesis y usos de los mismos | |
PH12019500188A1 (en) | Piperidine cxcr7 receptor modulators | |
CO2021005509A2 (es) | Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos | |
EA201792374A1 (ru) | Азабензимидазолы и их применение в качестве модуляторов рецептора ampa | |
CL2016002089A1 (es) | Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
CL2018000363A1 (es) | Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana. | |
CL2017001720A1 (es) | Nuevos derivados de bencimidazol como agentes antihistamínicos. | |
EA202190217A1 (ru) | Формы ивосидениба и фармацевтические композиции | |
CO2019004143A2 (es) | Compuestos azaheterocíclicos fusionados y su uso como moduladores de los receptores ampa | |
CL2017002605A1 (es) | Derivados de indol | |
MX2023010823A (es) | Degradadores selectivos del receptor de estrogeno. | |
MX369806B (es) | Compuestos de indolona y su uso como moduladores del receptor ampa. | |
UY38337A (es) | Formulaciones de dendrímeros | |
EA201992844A1 (ru) | Новые пероральные составы на основе белиностата | |
BR112018012030A2 (pt) | composição para redução da frequência de urinação, método de produção e uso da mesma | |
EA201991734A1 (ru) | Модуляторы рецептора эстрогена |